Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Preoperative bone scans were obtained in 104 patients with operable breast cancer. Areas of increased radioactivity detected by the bone scan were correlated with appropriate radiographs. One of 64 patients (1.5%) with clinical Stage I and Stage II breast cancer had a metastatic lesion detected by the preoperative bone scan. In contrast, 10 of 41 patients (24%) with Stage III breast cancer had occult metastatic lesions detected by the preoperative bone scan. The majority of patients with abnormal bone scans and no radiographic evidence of a benign lesion to explain the cause of the increased radioactivity proved to have metastatic breast cancer on follow-examination. Even though 20% of patients with operable breast cancer will eventually develop
bone metastases
, our results indicate that preoperative bone scans are not an effective means of predicting which patients with Stage I and Stage II disease will develop metastatic breast cancer. Because of the considerably increased frequency of detection of occult
metastases
in patients with Stage III breast cancer, bone scans should be obtained routinely in the preoperative assessment of these patients.
...
PMID:An evaluation of bone scans as screening procedures for occult metastases in primary breast cancer. 88 78
Bony metastases
in association with a lesion in the lung are usually regarded as secondary to bronchial carcinoma. This is generally true when the
metastases
are osteolytic. However, in the presence of a solitary lung lesion with osteoblastic
metastases
, the diagnosis of bronchial carcinoid should be considered. The following case illustrates this point.
...
PMID:Bronchial carcinoid with osteoblastic metastases. 92 95
In the treatment of breast cancer a radiation therapy is indicated under the following conditions: 1. Postoperative irradiation only of the regional lymph-nodes also in stage I (T1, N0). 2. Postoperative irradiation of the regional lymph-nodes and the thorax wall in cases with great primary tumours (T2), in cases with involved axillary lymph-nodes and, of course, in all cases with "grave signs". 3. Preoperative irradiation only in those cases when it seems possible that an inoperable tumour would become operable. 4. As the sole local treatment only in cases with very large inoperable tumours or in special cases (e.g. very high risc or refusal of the operation). 5. As local treatment of a local recidive or of isolated
metastases
. 6. As supporting local therapy (e.g. threatening fracturation of our fracturated
bone metastases
; brain metastases) in cases of generalized
metastatic disease
treated by hormonal or cytostatic therapy.
...
PMID:[Radiotherapy in the treatment of breast carcinoma]. 95 35
In 181 consecutive patients with breast cancer, urinary hydroxyproline excretion has been critically evaluated in conjunction with clinical, biochemical, radiological and scintigraphic parameters. The urinary hydroxyproline/creatinine ratio is a sensitive index of the presence of
bone metastases
. Urinary hydroxyproline excretion is a reliable method of selecting those patients whose elevated serum alkaline phosphatase is secondary to bone disease rather than liver idsease. The estimation of hydroxyproline excretion furthermore gives information on the activity of bone metastasis, and its response to treatment, which cannot be given by radiological or scintigraphic methods. It is doubtful whether urinary hydroxyproline estimation will help to detect
bone metastases
before they are apparent on scintigrams. When the bone scan is doubtful, as often occurs in older subjects, hydroxyproline excretion has been found to be helpful in classifying the patient. When scintigraphy is not available, an elevation of hydroxyproline excretion, together with an elevation of Ca/cr ratio or alkaline phosphatase activity, may pre-date by several months the radiological demonstration of osseous
metastases
.
...
PMID:Relevance of hydroxyproline excretion to bone metastasis in breast cancer. 97 1
Patients (219) with prostatic adenocarcinoma were classified on the basis of whether or not their bone scans were positive for metastasis. Acid and alkaline phosphatase determinations and clinical evaluations for
bone metastases
were reviewed. Of those with proved
metastases
, 43% had no bone pain, 39% had normal acid phosphatase levels, 23% normal alkaline phosphatase levels, 19% normal levels of both enzymes, and 15% normal enzyme levels without bone pain. Twenty-four per cent of the patients with normal enzyme levels and clinically unsuspected
bone metastases
had bone scans which proved positive for metastasis; 62% of these had normal radiographs.
...
PMID:Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. 98 22
In a retrospective study of 305 patients with primary inoperable cancer of the breast, the over-all survival rate at five years was 12 per cent for those presenting with extensive lesions of the breast alone and 5 to 7 per cent for those with distant
metastases
. There was little difference in the survival times for any group within the study. Primary inoperable remains a useful classification for predicting prognosis. All survival curves suggested that distant
metastases
were present when the patients were first seen, whether obvious or not, and early use of combination chemotherapy for all patients is encouraged. Radiation therapy was the most effective treatment in terms of survival times for patients with local lesion. Palliative mastectomy after radiation therapy increased local control but not survival times. The influence of distant
metastases
on prognosis reflected both the site of
metastases
and the over-all extent of involvement.
Bone metastases
did not seem to detract from survival times as much as extensive lesions of the breast did when either of these sites of involvement accompanied other
metastases
. Outlook was so poor for patients with advanced lesions of the breast plus disease in the pleura and lung or in the liver that the early use of the most effective therapy available is encouraged. Endocrine ablation in these patients with no predictive criteria available was as effective as in those patients with recurrent inoperable cancer and favorable selection factors present.
...
PMID:Primary inoperable cancer of the breast. 99 9
Based on our prior experience in treating children with metastatic osteogenic sarcoma, a multidrug regimen was developed. Nine children with evaluable osteogenic sarcoma were treated with vincristine 1.5 mg/m2 on day 1, highdose methotrexate 200-300 mg/kg i.v. on day 2, with p.o. citrovorum factor "rescue" 9 mg every 6 hours x 12, followed in 2 weeks by cyclophosphamide 40 mg/kg i.v., then 2 weeks later Adriamycin 1.5 mg/kg/day x 2; in 2 weeks cyclophosphamide was repeated. After a 2-week rest, the 56-day cycle was repeated for a total period of 1 year. Oropharyngeal mucositis was the most frequent severe manifestation of gastrointestinal toxicity. Hematologic depression was mild to severe. Nine patients with clinically evaluable osteogenic sarcoma and no previous chemotherapeutic treatment were treated with this regimen. One patient had only a transient shrinkage in tumor mass, and one patient had no progression of multiple pulmonary and
bone metastases
for 16 months while on therapy. Of the remaining seven patients, all had clinically significant responses with tumor regression demonstrated for from 5 to 20+ months. Four of these patients (three presenting with primary tumor and pulmonary
metastases
) demonstrated regression of their primary tumor. In an attempt to increase the cure rate in osteogenic sarcoma, chemotherapy that has proven to be effective against metastatic osteogenic sarcoma should now be employed as prophylactic therapy, after amputation, at cancer treatment centers where it can be safely and effectively administered.
...
PMID:The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. 107 42
Bone scanning is most useful in the detection of
bone metastases
. The recent introduction of new radiopharmaceuticals and instrumentation has reduced the time needed to perform the study and its relative cost, while increasing the usefulness of the study in detecting roentgenographically occult diseases.
Metastatic disease
is used as the pathophysiologic model for understanding the principles of bone scanning. When a tumor invades bone, in addition to causing bone destruction, it also causes reactive bone formation or repair. It is here that radioisotopes are of considerable value, since some radionuclides are incorporated into the hydroxyapatite crystals of reactive bone. Bone repair is described as occurring in three phases. In Phase I, the roentgenogram shows no change in bone density, but the scan is abnormal. In Phase II, both scintigraphic and roentgenographic abnormalities increase, and in Phase III, when the osteoid has calcified completely, the roentgenogram shows radiodensities and the scan appears almost normal. Fewer than 5 per cent of patients have a normal scan in the presence of an abnormal roentgenogram. Presently, most bone scans are performed with phosphate compounds labeled with -99m-Tc. In the past, 85-Sr, 87M-Sr, and 18-F were more broadly used. Scanning may be performed on either a rectilinear scanner or a scintophoto (gamma) camera. Areas which are abnormal on bone scan should be interpreted with current roentgenograms in the light of clinical findings.
...
PMID:Bone scanning: principles, technique and interpretation. 109 63
Comparison of the gamma camera bone scan and radiological survey in 190 patients with breast cancer has confirmed the superiority of the bone scan in the positive diagnosis of skeletal
metastases
. In 47 patients with known (X-ray positive) bony
metastases
the scan was positive in all but 2, and in 24 (50 per cent) the scan showed more lesions than the X-ray had indicated. In 60 patients with a clinical suspicion of
bone metastases
but negative X-rays, the scan was positive in 29 (48 per cent). Eighty-three patients with primary breast cancer were studied at the time of initial presentation. All had a normal radiographic skeletal survey but 24 (27 per cent) had scan evidence of occult
metastases
. It is concluded that a bone scan is indicated in all patients with breast cancer where skeletal
metastases
are suspected. Repeated bone scans may introduce new therapeutic possibilities, by providing an earlier objective index of progression of
metastatic disease
and also by providing a quantitative method of assessing the response to therapy.
...
PMID:The application of the 99Tcm phosphate bone scan to the study of breast cancer. 112 58
Strontium nitrate Sr 87m bone scans were made preoperatively in a group of women with suspected breast cancer, 35 of whom subsequently underwent radical mastectomy. In 3 of the 35 (9%), the scans were abnormal despite the absence of clinical or roentgenographic evidence of
metastatic disease
. All three patients has extensive axillary lymph node involvement by tumor, and went on to have additional
bone metastases
, from which one died. Roentgenograms failed to detect the
metastases
in all three. Occult
bone metastases
account in part for the failure of radical mastectomy to cure some patients with breast cancer. It is recommended that all candidates for radical mastectomy have a preoperative bone scan.
...
PMID:Preoperative bone scans. Use in women with early breast cancer. 117 64
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>